http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 01 Jul 2026 09:30:17 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/NewcelX+gets+FDA+feedback+supporting+NCEL-101+diabetes+trial+path/26718076.html <p>NewcelX Ltd. (Nasdaq: NCEL) announced it has completed a Type B Pre-IND meeting with the U.S. Food and Drug Administration, receiving feedback that supports the company's proposed development strategy for NCEL-101, its stem cell-derived islet product candidate for type 1 diabetes.</p> <p>The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program, allowing the company to proceed toward Investigational New Drug enabling activities. The planned clinical trial would combine NCEL-101 with tegoprubart, an investigational anti-CD40L antibody developed by Eledon Pharmaceuticals (Nasdaq: ELDN).</p> <p>Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we http://www.streetinsider.com/FDA/NewcelX+gets+FDA+feedback+supporting+NCEL-101+diabetes+trial+path/26718076.html Wed, 01 Jul 2026 09:30:17 -0400 ELDN NCEL http://www.streetinsider.com/FDA/NewcelX+gets+FDA+feedback+supporting+NCEL-101+diabetes+trial+path/26718076.html <p>NewcelX Ltd. (Nasdaq: NCEL) announced it has completed a Type B Pre-IND meeting with the U.S. Food and Drug Administration, receiving feedback that supports the company's proposed development strategy for NCEL-101, its stem cell-derived islet product candidate for type 1 diabetes.</p> <p>The FDA provided favorable feedback on NewcelX's Chemistry, Manufacturing, and Controls processes and preclinical program, allowing the company to proceed toward Investigational New Drug enabling activities. The planned clinical trial would combine NCEL-101 with tegoprubart, an investigational anti-CD40L antibody developed by Eledon Pharmaceuticals (Nasdaq: ELDN).</p> <p>Ronen Twito, CEO and Executive Chairman of NewcelX, said: "Coming out of our FDA meeting, we http://www.streetinsider.com/FDA/NewcelX+gets+FDA+feedback+supporting+NCEL-101+diabetes+trial+path/26718076.html Wed, 01 Jul 2026 09:30:17 -0400 ELDN NCEL http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Successful+FDA+Pre-IND+Meeting+with+Clear+Path+Forward+for+NCEL-101+Toward+Starting+Clinical+Trials+for+Type+1+Diabetes/26718062.html <p><strong>FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart</strong></p><p align="justify">ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL),</strong> a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration (“FDA”). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (Nasdaq: ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results http://www.streetinsider.com/Press+Releases/NewcelX+Announces+Successful+FDA+Pre-IND+Meeting+with+Clear+Path+Forward+for+NCEL-101+Toward+Starting+Clinical+Trials+for+Type+1+Diabetes/26718062.html Wed, 01 Jul 2026 09:30:00 -0400 ELDN http://www.streetinsider.com/Globe+Newswire/NewcelX+Announces+Successful+FDA+Pre-IND+Meeting+with+Clear+Path+Forward+for+NCEL-101+Toward+Starting+Clinical+Trials+for+Type+1+Diabetes/26718062.html <p><strong>FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart</strong></p><p align="justify">ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL),</strong> a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration (“FDA”). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (Nasdaq: ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results http://www.streetinsider.com/Globe+Newswire/NewcelX+Announces+Successful+FDA+Pre-IND+Meeting+with+Clear+Path+Forward+for+NCEL-101+Toward+Starting+Clinical+Trials+for+Type+1+Diabetes/26718062.html Wed, 01 Jul 2026 09:30:00 -0400 ELDN http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/FDA/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html <p>Natera, Inc. (Nasdaq: NTRA) and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) have announced a partnership to use Natera's Prospera kidney transplant assessment test in Eledon's planned Phase 3 clinical trial of tegoprubart, an investigational drug intended to prevent organ rejection in kidney transplantation.</p> <p>Under the agreement, the Prospera test will serve as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in the trial. The study is expected to enroll approximately 600 kidney transplant recipients across more than 100 transplant centers globally, with trial initiation planned for late 2026.</p> <p>Tegoprubart is an anti-CD40L antibody being developed as an alternative to current immunosuppressive therapies such http://www.streetinsider.com/Corporate+News/Natera+and+Eledon+partner+on+kidney+transplant+Phase+3+trial/26688002.html Thu, 25 Jun 2026 07:00:23 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Press+Releases/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719 http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html <p class="bwalignc"><i>Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026</i></p> <p> AUSTIN, Texas &amp; IRVINE, Calif.--(BUSINESS WIRE)-- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an investigational therapy designed http://www.streetinsider.com/Business+Wire/Natera+and+Eledon+Announce+Strategic+Partnership+for+Prospera%E2%84%A2+Monitoring+in+Planned+Phase+3+Kidney+Transplant+Trial/26687970.html Thu, 25 Jun 2026 07:00:00 -0400 A.50216951 ELDN NTRA O.05077750 O.07095043 O.48628719